Paradigm Asset Management CO LLC Editas Medicine, Inc. Transaction History

Paradigm Asset Management CO LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$9.99 - $21.35 $48,951 - $104,615	-4,900 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $15,930 - $24,342	-600 Reduced 10.91%	4,900 $130,000
Q3 2021 Nov 12, 2021	SELL	$39.27 - $72.94 $23,562 - $43,764	-600 Reduced 9.84%	5,500 $225,000
Q2 2021 Jul 30, 2021	SELL	$31.29 - $56.64 $12,516 - $22,656	-400 Reduced 6.15%	6,100 $345,000
Q1 2021 May 11, 2021	SELL	$39.71 - $90.58 $23,826 - $54,348	-600 Reduced 8.45%	6,500 $273,000
Q4 2020 Feb 12, 2021	BUY	$27.07 - $84.35 $192,197 - $598,885	7,100 New	7,100 $497,000

247

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $168M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Paradigm Asset Management CO LLC, based on Form 13F filings with the SEC.

Stay updated on Paradigm Asset Management CO LLC with notifications on news.